Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis

Annals of Transplantation

Volumn 17, Issue 4, 2012, Pages 82-91

  Al Jedai, Ahmed ^a,b   Alsultan, Mohammed ^c   Almeshari, Khalid ^a   Alshaibani, Khalid ^d   Elgamal, Hazem ^a   Alkortas, Delal ^a   Khurshid, Fowad ^c   Altalhi, Mai ^a   Hamawi, Khaled ^d  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Allosensitization; Cost analysis; Desensitization; Financial analysis; Positive cross match kidney transplantation

Indexed keywords

DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MAPAP; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DESENSITIZATION; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEALTH CARE COST; HEALTH SERVICE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; IMMUNOADSORPTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PLASMAPHERESIS; SINGLE DRUG DOSE; SURGICAL MORTALITY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; FOLLOW-UP STUDIES; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SAUDI ARABIA; SORPTION DETOXIFICATION; TREATMENT OUTCOME;

EID: 84875288094     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883698     Document Type: Article

References (42)

1. Sayegh MH, Carpenter CB: Transplantation 50 years later-progress, challenges, and promises. N Engl J Med, 2004; 351: 2761-66
2. Wolfe RA, Ashby VB, Milford EL et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 1999; 341: 1725-30
3. Evans RW, Manninen DL, Garrison LP Jr et al: The quality of life of patients with end-stage renal disease. N Engl J Med, 1985; 312: 553-59
4. Port FK, Wolfe RA, Mauger EA et al: Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA, 1993; 270: 1339-43
5. Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation-a prospective study. Transplantation, 1992; 54: 656-60
6. Yen EF, Hardinger K, Brennan DC et al: Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant, 2004; 4: 1703-8
7. Marcen R: Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs, 2009; 69: 2227-43
8. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med, 1969; 280: 735-39
9. van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MF et al: Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation, 2002; 74: 1114-19
10. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant, 2007; 7: 408-15
11. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant, 2004; 4: 438-43
12. Gebel HM, Bray RA, Nickerson P: Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant, 2003; 3: 1488-500
13. Zhou YC, Cecka JM: Sensitization in renal transplantation. Clin Transpl, 1991: 313-23
14. Glotz D, Antoine C, Julia P et al: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant, 2002; 2: 758-60
15. Hiesse C, Kriaa F, Rousseau P et al: Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant, 1992; 7: 944-51
16. Jordan SC, Vo A, Bunnapradist S et al: Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation, 2003; 76: 631-36
17. Thielke J, DeChristopher PJ, Sankary H et al: Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc, 2005; 37: 643-44
18. Jin Q, Liu H, Song LY et al: Protein A immunoadsorption therapy in the highly sensitized kidney transplant candidates. Chin Med J (Engl), 2011; 124: 780-82
19. Montgomery RA, Zachary AA, Racusen LC et al: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchpositive recipients. Transplantation, 2000; 70: 887-95
20. Tanriover B, Wright SE, Foster SV et al: Highdose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc, 2008; 40: 3393-96
21. Kaposztas Z, Podder H, Mauiyyedi S et al: Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant, 2009; 23: 63-73
22. Faguer S, Kamar N, Guilbeaud-Frugier C et al: Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-80
23. Jordan SC, Vo AA, Toyoda M et al: Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant, 2005; 9: 155-61
24. Wadstrom J, Gannedahl G, Bersztel A et al: Successful kidney transplantation after suppression of HLA alloantibodies with intravenous immunoglobulin in a highly sensitized patient. Transplant Proc, 1995; 27: 3463-64
25. Tyan DB, Li VA, Czer L et al: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation, 1994; 57: 553-62
26. Glotz D, Haymann JP, Sansonetti N et al: Suppression of HLA-specific alloantibodies by highdose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation, 1993; 56: 335-37
27. Al-Meshari K, Al-Shaibani K, Hamawi K et al: The Kidney Transplant Program at King Faisal Specialist Hospital and Research Center. Clin Transpl, 2005: 119-29
28. Simon DG: A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. Med Decis Making, 1986; 6: 199-207
29. Bohmig GA, Wahrmann M, Regele H et al: Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant, 2007; 7: 117-21
30. Glotz D, Antoine C, Julia P et al: Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int, 2004; 17: 1-8
31. Jordan S, Cunningham-Rundles C, McEwan R: Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant, 2003; 3: 653-64
32. Kalo Z, Jaray J, Nagy J: Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary. Prog Transplant, 2001; 11: 188-93
33. Haller M, Gutjahr G, Kramar R et al: Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant, 2011; 26: 2988-95
34. Salonen T, Reina T, Oksa H et al: Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis, 2003; 42: 1228-38
35. You J, Hoy W, Zhao Y et al: End-stage renal disease in the Northern Territory: current and future treatment costs. Med J Aust, 2002; 176: 461-65
36. Loubeau PR, Loubeau JM, Jantzen R: The economics of kidney transplantation versus hemodialysis. Prog Transplant, 2001; 11: 291-97
37. Mauiyyedi S, Colvin RB: Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens, 2002; 11: 609-18
38. Lefaucheur C, Nochy D, Hill GS et al: Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant, 2007; 7: 832-41
39. Schwenger V, Morath C: Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant, 2010; 25: 2407-13
40. Montgomery RA, Lonze BE, King KE et al: Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med, 2011; 365: 318-26
41. Schnitzler MA, Lentine KL, Burroughs TE: The cost effectiveness of deceased organ donation. Transplantation, 2005; 80: 1636-37
42. U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010